MA47408A - Traitement du cancer - Google Patents
Traitement du cancerInfo
- Publication number
- MA47408A MA47408A MA047408A MA47408A MA47408A MA 47408 A MA47408 A MA 47408A MA 047408 A MA047408 A MA 047408A MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer treatment
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17209098 | 2017-12-20 | ||
| PCT/EP2018/052694 WO2018141921A1 (fr) | 2017-02-06 | 2018-02-02 | Traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47408A true MA47408A (fr) | 2019-12-11 |
| MA47408B1 MA47408B1 (fr) | 2023-08-31 |
Family
ID=60702421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47408A MA47408B1 (fr) | 2017-12-20 | 2018-02-02 | Traitement du cancer |
Country Status (5)
| Country | Link |
|---|---|
| EA (1) | EA201991818A1 (fr) |
| MA (1) | MA47408B1 (fr) |
| PT (1) | PT3576740T (fr) |
| TW (1) | TWI798199B (fr) |
| WO (1) | WO2018141921A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019342289A1 (en) * | 2018-09-21 | 2021-03-18 | Janssen Pharmaceutica Nv | Treatment of cholangiocarcinoma |
| CN113474337A (zh) * | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物 |
| WO2020165181A1 (fr) * | 2019-02-12 | 2020-08-20 | Janssen Pharmaceutica Nv | Traitement contre le cancer |
| CA3133348A1 (fr) * | 2019-03-15 | 2020-09-24 | Poly-Med, Inc. | Systemes d'administration, methodes et compositions formant un gel in situ |
| CA3130773A1 (fr) * | 2019-03-29 | 2020-10-08 | Peter Marie Z. De Porre | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothelial |
| WO2020205493A1 (fr) * | 2019-03-29 | 2020-10-08 | Janssen Pharmaceutica Nv | Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial |
| JP2022534118A (ja) * | 2019-05-31 | 2022-07-27 | キューイーディー セラピューティクス,インコーポレイテッド | 泌尿器系がんを治療する方法 |
| CA3176713A1 (fr) * | 2019-12-09 | 2021-06-17 | Cedars-Sinai Medical Center | Utilisation d'inhibiteurs de fgfr pour le traitement de sujets presentant un retard de croissance idiopathique |
| TWI900527B (zh) * | 2020-02-12 | 2025-10-11 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑 |
| JP2023513704A (ja) * | 2020-02-12 | 2023-04-03 | ヤンセン ファーマシューティカ エヌ.ベー. | 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤 |
| US20230381196A1 (en) * | 2020-09-17 | 2023-11-30 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200201A1 (ar) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
-
2018
- 2018-02-02 MA MA47408A patent/MA47408B1/fr unknown
- 2018-02-02 PT PT187022991T patent/PT3576740T/pt unknown
- 2018-02-02 TW TW107103846A patent/TWI798199B/zh active
- 2018-02-02 EA EA201991818A patent/EA201991818A1/ru unknown
- 2018-02-02 WO PCT/EP2018/052694 patent/WO2018141921A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018141921A1 (fr) | 2018-08-09 |
| EA201991818A1 (ru) | 2020-02-05 |
| TW201839399A (zh) | 2018-11-01 |
| TWI798199B (zh) | 2023-04-11 |
| MA47408B1 (fr) | 2023-08-31 |
| PT3576740T (pt) | 2023-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3488001A4 (fr) | Traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| IL255261A0 (en) | Methods for treating cancer | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| MA47408A (fr) | Traitement du cancer | |
| EP3388004A4 (fr) | Instrument de traitement | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| EP3621592A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| MA41555A (fr) | Polythérapie pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3432888A4 (fr) | Traitement du cancer avec tg02 | |
| PL3197456T3 (pl) | Leczenie nowotworów | |
| EP3606531A4 (fr) | Méthodes de traitement du cancer | |
| MA45429A (fr) | Polythérapie pour le traitement du cancer | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| PT3458052T (pt) | Tratamento combinado do cancro | |
| MA52627A (fr) | Traitement du cancer | |
| EP3546020C0 (fr) | Appareil de traitement du cancer | |
| EP3375108A4 (fr) | Traitement dewlan | |
| MA46361A (fr) | Traitement du cancer de la prostate | |
| EP3733175A4 (fr) | Traitement du cancer | |
| EP3610026A4 (fr) | Méthodes de traitement du cancer de la vessie | |
| DK3576740T3 (da) | Cancerbehandling |